Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 130 of 144 pages ‹ First < 128 129 130 131 132 > Last ›
HSL10255
Ariza Ariza R.
How to avoid the gastrointestinal pain in the treatment of arthrosis. Cost-benefit approximation of the different alternatives in the Spanish market
Seminarios de la Fundacion Espanola de Reumatologia 2003; 4:(3):93-103
HSL10256
Promise of patent extension in return for studies in children improves safety
Pharmaceutical Journal 2003; 271:(7265):288
HSL10257
Coloured-pack generic range to expand
Pharmaceutical Journal 2003; 271:(7265):286
HSL10258
Chapman LWJ.
Opening a can of worms [1]
Pharmaceutical -Journal 2003; 271:(7264):260
HSL10260
Abraham J.
Learning from drug disasters and reforming medicines regulation
Critical Public Health 2003; 13:(3):269-279
HSL10262
Rapley M.
I want, therefore I am: A tribute to David Smail
Clinical Psychology 2003; (24):13-19
HSL10268
Tent M.
Why doctors sometimes prescribe drugs which are more expensive than necessary: Favors can get under your skin
Pharmaceutisch Weekblad 2003; 138:(33-34):1163
HSL10271
Bjornsdottir I, Hansen EH, Grimsson A.
Choosing among antibiotic products: General practitioners' path while prescribing
Journal of Social and Administrative Pharmacy 2003; 20:(4):118-124
HSL10272
Buying medicines on the world wide web: What is legal and what is not?
Pharmaceutical Journal 2003; 271:(7262):202
HSL10273
CoMedis aims for 4,000 online users
Pharmaceutical Journal 2003; 271:(7262):198
HSL10274
Lifting advertising ban could lead to more switches to pharmacy medicines
Pharmaceutical Journal 2003; 271:(7262):198
HSL10275
World wide worry
Pharmaceutical Journal 2003; 271:(7262):194
HSL10276
Abasolo E, Hermosilla-najera L, Guijarro J, Ramos-saiz EM, Abecia LC.
Minimised antimicrobial cost analysis at a Health Care Centre
Pharmaceutical Care Espana 2003; 5:(3):132-8
HSL10277
Medicines in mind
Veterinary Record 2003; 153:(8):221
HSL10278
Morphine oral - Elan Corporation: Avinza
Drugs in R and D 2003; 3:(3):208-209
HSL10280
Shipman inquiry: Views on tightening of controlled drug regulations sought
Pharmaceutical Journal 2003; 271:(2761):171-172
HSL10281
Balit CR, Isbister GK, Dawson A, Daly FF, Whyte IM, Hender EA, Raftos J, Kisely SR, Lawrence D, Preston NJ.
The effect of recalling paracetamol on hospital admissions for poisoning (multiple letters)
Medical Journal of Australia 2003; 179:(4):221-3
HSL10282
Telithromycine and myasthenia gravis
WHO Drug Information 2003; 17:(2):104-105
HSL10288
Kang JY, Majeed A, Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL.
Hospitalization and mortality rates from peptic ulcer in the 1990s [3] (multiple letters)
American Journal of Gastroenterology 2003; 98:(8):1896-1897
http://ezproxy.library.uq.edu.au/login?url=http://dx.doi.org/10.1016/S0002-9270(03)00502-1 Blackwell-Synergy http://www.blackwell-synergy.com/rd.asp?code=AJG&vol=98&page=1896&goto=abstract
HSL10290
Support for changes in BVA structure
Veterinary Record 2003; 154:(4):101-104
HSL10291
Wang L.
AstraZeneca pleads guilty to criminal conspiracy
Journal of the National Cancer Institute 2003; 95:(14):1037
HSL10354
New stroke warning for OTC products
Pharmaceutical Journal 2003; 271:(7257):39
HSL10357
Birkett DJ.
Generics - Equal or not?
Australian Prescriber 2003; 26:(4):85-87
HSL10363
Performance of sales representatives in France: Still bad
Prescrire International 2003; 12:(66):153
HSL10364
Paroxetine withdrawal syndrome
Prescrire International 2003; 12:(66):141
HSL10365
Zofenopril
Prescrire International 2003; 12:(66):140
HSL10367
Wechsler J.
Debate escalates over follow-on biologics
BioPharm International 2003; 16:(7):12-14
HSL10368
Harman RJ.
Legislation for medicines and product liability - A review of UK and European controls
Pharmaceutical Journal 2003; 270:(7255):904
HSL10372
Golubtsov B, Kermani F.
Coming of age in CEE
Good Clinical Practice Journal 2003; 10:(7):15-18
HSL10374
Baele PL.
Miss-'n-mix and mimics Batch DM 998
Acta Anaesthesiologica Belgica 2003; 54:(2):149-150
HSL10375
Reissman D.
Selling the benefits of mail
Drug Benefit Trends 2003; 15:(6):
HSL10376
Wechsler J.
Changes in Congress and FDA shape healthcare policy
Formulary 2003; 38:(2):113-115
HSL10379
Wechsler J.
Bush budget outlines healthcare priorities
Formulary 2003; 38:(3):168-171
HSL10380
Clarke PMW.
Educate the public by making supplements P medicines [7]
Pharmaceutical Journal 2003; 270:(7249):682
HSL10381
Altagracia MM, Kravzov JJ, Moreno SR, Rios CC, Vazquez ME.
Self-medication in rural and urban communities in the state of Guerrero, Mexico
Revista Mexicana de Ciencias Farmaceuticas 2003; 34:(2):27-35
HSL10382
Gomez BJV, De-denis ME, Pereda-reyna O.
Antihypertensive medications used by specialist physicians and factors that influence the prescription
Revista Mexicana de Ciencias Farmaceuticas 2003; 34:(2):21-26
HSL10411
Most pharmacists recommend most medicines they sell
Pharmaceutical Journal 2003; 270:(7253):817
HSL10412
Evaluating e-pharmacy
Medicine Today 2003; 4:(6):
HSL10413
Lowe R.
There should be one brand name for one drug
Pharmaceutical Journal 2003; 270:(7252):792
HSL10416
Dewa CS, Hoch JS.
Fixed and flexible formularies as cost-control mechanisms
Expert Review of Pharmacoeconomics and Outcomes Research 2003; 3:(3):303-315
HSL10417
Broom D.
Big yellow taxi, or, unhealthy terms of trade?
Aust N Z J Public Health 2003; 27:(3):271-2
HSL10418
Any questins?
Veterinary Record 2003; 152:(22):672-674
HSL10419
Pharmacists propose new POM category
Veterinary Record 2003; 152:(22):670
HSL10420
An uphill struggle on medicines
Veterinary Record 2003; 152:(22):669-670
HSL10421
Hughes I.
Let us hope a door may be opened to further discussion - Campaign summary
Pharmaceutical Journal 2003; 270:(7251):750-751
HSL10422
Omeprazole to be a pharmacy medicine
Pharmaceutical Journal 2003; 270:(7250):709
HSL10423
Seligman PJ.
'Dear doctor....' - Evaluating the impact of risk communication efforts
Pharmacoepidemiology and Drug Safety 2003; 12:(4):291-293
HSL10427
Arbuckle JBR.
Supply of POMs
Veterinary Record 2003; 152:(21):667-668
HSL10428
Medicines in Europe campaign
Prescrire International 2003; 12:(65):115
HSL10430
Major therapeutic advances are rare
Prescrire International 2003; 12:(63):31
HSL10431
A needless addition to the other macrolides
Prescrire International 2003; 12:(63):8-11
HSL10467
Medicines Australia Code of Conduct
Australian Prescriber 2003; 26:(3):66
HSL10468
Topical use of Lindane
WHO Drug Information 2003; 17:(1):26-28
HSL10469
Richardson R, Shaw I, Nolan S.
A perspective on New Zealand's medicines regulatory environment
International Journal of Pharmaceutical Medicine 2003; 17:(1):17-22
HSL10471
George Wong HC
Potential reactions to patent medicines containing prescription drugs
Allergy and Clinical Immunology International 2003; 15:(3):114-118
HSL10476
First statin patent expires amid OTC speculation
Pharmaceutical Journal 2003; 270:(7247):603
HSL10477
Pharmacists believe EHC is too costly
Pharmaceutical Journal 2003; 270:(7247):603
HSL10478
From the supply of POMs to proposed changes in the BVA'S structure
Veterinary Record 2003; 152:(19):575-578
HSL10479
OFT acts on the supply of POMs
Veterinary Record 2003; 152:(19):574
HSL10480
Schulze J, Raasch W, Siegers CP.
Toxicity of kava pyrones, drug safety and precautions--a case study.
Phytomedicine 2003; 10:
HSL10484
New therapies drive up cost of GI medications
Drug Benefit Trends 2003; 15:6-7
HSL10498
Bad medicine
Veterinary Record 2003; 152:(16):481
HSL10499
Vet medicines monopoly to be broken
Pharmaceutical Journal 2003; 270:(7245):534
HSL10500
Cheng JWM.
Bosentan
Heart Disease 2003; 5:(2):161-169
HSL10504
How genetics could change pharmacy
Pharmaceutical Journal 2003; 270:(7244):508-509
HSL10505
Medicine imports and exports rising
Pharmaceutical Journal 2003; 270:(7244):501
HSL10506
Hemels MEH, Bennett HA, Bonari L, Han D, Traverso ML, Einarson TR.
HOPE study impact on ACE inhibitors use
Annals of Pharmacotherapy 2003; 37:(5):640-645
HSL10507
Maskrey N, Jackson C, Critchlow H.
Support to consider the resource implications of NICE guidance
Journal of Clinical Excellence 2003; 4:(3):306-309
HSL10508
Toop L, Richards D, Dowell T.
The leadership role of general practice in public health: advocating a ban of direct-to-consumer advertising of prescription drugs in New Zealand; 'Possums in the headlights?'.
British Journal of General Practice 2003; 53:(489):342-345
http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000489;jsessionid=1dei97cpjj6ai.henrietta?
HSL10510
Wolfe SH.
Ephedra - Scientific evidence versus money/politics
Science 2003; 300:(5618):437
HSL10511
Slade RFJ.
Why the change from 14-disk to 15-disk packs? [3]
Pharmaceutical Journal 2003; 270:(7243):476
HSL10512
DTB advocates prescription of injectable adrenaline for children
Pharmaceutical Journal 2003; 270:(7242):427
HSL10514
Manufacturer claims superior action for new statin
Pharmaceutical Journal 2003; 270:(7242):427
HSL10515
Supplementary prescribing legal from next week
Pharmaceutical Journal 2003; 270:(7242):424
HSL10517
Links.
Compliance Policy Guide on Chapter 4 Human Drugs: Section 460.200 Pharmacy Compounding.
J Pain Palliat Care Pharmacother 2003; 17:(1):99-106
HSL10518
Hildebrand JR.
Report from the USA
Pharmazeutische Industrie 2003; 65:(3):247-251
HSL10520
Theodorou AA.
How 3-tier plan design and other strategies yielded $1.6 billion in cost savings
Drug Benefit Trends 2003; 15:(3):45-54
HSL10521
IJPP given a new look and is now fully available online
Pharmaceutical Journal 2003; 270:(7241):410-411
HSL10522
Armendariz M, Armendariz M, Jaio N, Gorostiza I.
Impact of new non-steroid anti-inflammatory drugs in Primary Care prescription
Pharmaceutical Care Espana 2003; 5:(1):29-38
HSL10523
Roy V, Goyal RK.
Of societies and issues (multiple letters)
Indian Journal of Pharmacology 2003; 35:(2):116-118
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=35&issue=2&spage=116
HSL10524
Lam W.
Off-label promotion and prescribing of gabapentin [2]
Australian Prescriber 2003; 26:(2):28
HSL10525
Krznaric Z.
Drugs in gastroenterology
Medicus 2003; 11:(1):67-78
HSL10530
Achanta AS.
OTC switch case history evaluation: NicoretteR
Clinical Research and Regulatory-Affairs 2003; 20:(1):15-26
HSL10531
Schmidt RJ.
Generic specifications for standard products needed [16]
Pharmaceutical Journal 2003; 270:(7233):116-117
HSL10532
Scrap contract regulations, says OFT
Pharmaceutical Journal 2003; 270:(7233):103
HSL10533
Dismal science sells pharmacy short
Pharmaceutical Journal 2003; 270:(7233):102
HSL10534
Eberwein B, Schulz R.
Allensbach study phytopharmaceutics in 2002, part 2
Schweizerische Zeitschrift fur GanzheitsMedizin 2003; 15:(2):87-93
HSL10536
Boots keeps its spot as biggest health retailer in Europe
Pharmaceutical Journal 2003; 270:(7240):360
HSL10537
Simmonds H.
The role of the PMCPA explained [13]
Pharmaceutical Journal 2003; 270:(7239):334-335
HSL10541
Robinson K.
A rocky road for generics
BioPharm International 2003; 16:(1):24-26
HSL10542
Moulds RFW.
Good prescribing: Where to next?
Medical Journal of Australia 2003; 178:(5):196-197
HSL10544
Wade OL.
The British National Formulary - Memoirs of a former chairman
Pharmaceutical Journal 2003; 270:(7237):278-281
HSL10545
Kempner N.
Planning ahead: Are customers sick of smoking?
Pharmaceutical Journal 2003; 270:(7237):273
HSL10546
McNulty H.
Putting children first [19]
Pharmaceutical Journal 2003; 270:(7237):269
HSL10547
Mason J.
Is the marketing of pharmaceuticals a matter of style over substance?
Pharmaceutical Journal 2003; 270:(7237):264
HSL10620
Neto A.
Changing pharmacy practice: The Australian experience
Pharmaceutical Journal 2003; 270:(7236):235-236
HSL10623
Murthy JMK.
Some problems and pitfalls in developing countries
Epilepsia 2003; 44:(1):38-42
http://www.blackwell-synergy.com/rd.asp?code=EPI&vol=44&page=38&goto=abstract
HSL10625
Cox AR.
Prescribers need appraisal training programmes [21]
Pharmaceutical Journal 2003; 270:(7234):154
HSL10626
Antiepileptics for migraine prophylaxis only cost-effective with frequent episodes
Expert Review of Pharmacoeconomics and Outcomes Research 2003; 3:(1):5-12
HSL10633
Sweet M.
Gabapentin documents raise concerns about off-label promotion and prescribing
Australian Prescriber 2003; 26:(1):18-19
Page 130 of 144 pages ‹ First < 128 129 130 131 132 > Last ›
